Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...
USWNT U23 squad: Roster of rising stars set to train in camp alongside senior team's international friendlies
A day after Emma Hayes dropped a 24-player roster for the upcoming April friendlies against Brazil, an additional U23 roster ...
Targeted Oncology6d
ST316 Shows Promise in Phase 1 Trial for Wnt/β-Catenin-Driven Cancers
ST316, a β-catenin/BCL9 antagonist, demonstrated safety, target engagement, and early antitumor activity in advanced solid ...
AlphaGalileo6h
Canonical and noncanonical NOTCH signaling in the nongenetic resistance of cancer: distinct and concerted control
Cancer remains a leading cause of death globally, with lung cancer being particularly lethal. Despite advancements in diagnostics and therapies, the ...
Mansfield News Journal on MSN20h
Taylor Huff gets call for USWNT U-23 Training Camp
On Wednesday, 2021 Madison grad and professional soccer player for Bay FC, Taylor Huff, received noticed that she has been ...
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...
EurekAlert!10d
New genetic insights into hypospadias: MAFB and CEBPA’s role in urothelial growth
A recent study has unveiled the critical roles of two transcription factors, MAFB and CEBPA, in the development of ...
News-Medical.Net on MSN10d
Researchers discover MAFB and CEBPA’s role in hypospadias pathogenesis
Hypospadias is characterized by an ectopic urethral opening and abnormal penile curvature, affecting approximately 1 in 200 live male births.
All Penny Stocks (English) on MSN20h
Micro Cap Soars Following Preliminary Data Update
Real-time index price for DJ Brent Crude Index (BBR), along with buy or sell indicators, analysis, charts, historical ...
EurekAlert!1d
Inhibition of PCSK9: a promising enhancer for anti-PD-1/PD-L1 immunotherapy
Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...
Allarity Therapeutics, Inc.: Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib-a differentiated ...